ABSTRACT Motivation: DNA microarrays allow the simultaneous measurement of thousands of gene expression levels in any given patient sample. Gene expression data have been shown to correlate with survival in several cancers, however, analysis of the data is difficult, since typically at most a few hundred patients are available, resulting in severely underdetermined regression or classification models.
INTRODUCTION
Expression profiles of tumors, measured by DNA microarrays, provide new insights into cancer ethiology. One important goal is to develop new tools to diagnose cancer and predict disease and treatment outcome more accurately based on gene expression profiles Rosenwald et al., 2002) , aiding the clinician with the decision on whether and how to commence treatment of a given patient. Classification of tumor samples to certain risk classes has been demonstrated to be a first step however, predicting actual survival times and distributions thereof for the individual patient is a widely desired goal.
Furthermore, the identification of genes that correlate with survival may provide new information on pathogenesis and ethiology, and may further aid in the search for new targets for drug design.
A serious problem in microarray data analysis comes from the fact that several thousand gene expression levels are measured simultaneously, while typically only several dozen to at most a few hundred patient samples are available . Mathematically, this yields models with thousands of unknowns, but only a very limited number of data points for parameter estimation. This main statistical problem of microarray experiments may explain in part the often diverging results in different studies on the same entity [e.g. Shipp et al., 2002) or (Bhattacharjee et al., 2001; Beer et al., 2002) ]. This is why data reduction methods such as principal component analysis (PCA) or clustering are normally used to reduce data dimensionality considerably before further analysis is carried out.
A problem of such two-step analysis using unsupervised learning methods is, that features identified by, for example, clustering or PCA may show large variability with clear subgroups, which are, however, unrelated to survival. The approach presented in this paper combines dimension reduction and regression in one single step, thus selecting the most discriminatory genes for the regression model automatically and optimizing regression parameters simultaneously. Several important questions can then be answered: First, which genes are related to survival, and how relevant are the individual genes? Second, continuous survival times or distributions over survival times conditioned on the gene expression values can be predicted, instead of merely classifying patients in two or three different risk classes. Finally, instead of grouping patients based on their gene expression levels and then relating those groups to survival, the method presented in this paper uses survival time as the main predictive variable, and directly looks for genes related to survival.
Ã To whom correspondence should be addressed. We used two examples of studies with more than 100 cases to test whether our algorithm is able to predict survival time and to yield meaningful genes responsible for the differences in survival. We present results on a dataset derived from patients with adenocarcinoma of the lung (LC). The main example discussed in this paper concerns diffuse large B-cell lymphoma (DLBCL), a cancer of B lymphocytes.
MATERIALS AND METHODS
Two publicly available datasets were analyzed. The dataset published by Bhattacharjee et al. (2001) on LC contains 125 samples with 12 600 expression values, measured on the U95A platform (Affymetrix). The second dataset published by Rosenwald et al. (2002) on DLBCL consist of 240 samples, with 7399 expression values measured on a cDNA array (lymphochip).
Prior to analysis by our method, data were subjected to preprocessing steps. On the LC dataset, first, microarray features with total variance <2500 were removed. This same step was carried out by Bhattacharjee et al. (2001) in their analysis. Data from the LC study are of much higher dimensionality than the DLBCL dataset, while at the same time only half as many samples are available. Therefore, we expected the analysis of the LC data to be much more difficult than the analysis of the DLBCL data. To address this issue, we reduced dimensionality by clustering features together using standard hierarchical clustering, with Pearson's correlation coefficient as similarity measure. Clusters were represented by their mean, and clustering was interrupted when similarity dropped below 0.5 for the first time, at which point the microarray features are clustered in 926 distinct clusters. Data were then normalized by subtracting the mean and changing the variance to one. Owing to the low sample number, leave-one-out crossvalidation was used on this dataset during analysis by our method.
The DLBCL data were split in training and validation subsets. To be able to compare results with previous work, the same split as in the original publication was used. A total of 160 patients were used for training, the remaining 80 for validation. Genes with >40% missing values or variance <0.45, determined on the training dataset only, were filtered out, leaving $3000 features in the computation. The data were then normalized as described for LC, without any further dimension reduction.
Survival time regression
Regression models over survival times are complicated because of the presence of censoring in the data. In a typical clinical study, performed over a predetermined time, patients enter the study as they are diagnosed, and leave the study either when the end point occurs (e.g. recurrence of disease, patient's death), when the study ends before the end point occurs or for reasons such as relocation or commencing a different treatment. In the latter two cases, survival times are right-censored, and this needs to be dealt with explicitely when carrying out regression analysis.
Let T be a random variable, representing the (potentially unobserved) survival time of a patient of interest. A popular regression model over survival times is the Cox regression model , postulating that the hazard, i.e. the immediate risk of failure at time t, given survival until t, is given by
where x is a vector of covariates (e.g. the measured gene expression levels), is the vector of regression parameters and l 0 (t) is an unspecified baseline hazard function, describing the hazard for some standard conditions x ¼ 0. Note that, given x and , the hazard l(t) completely specifies the survivor function F(t) ¼ P{T ! t} and the probability density f(t) ¼À dF(t)/dt.
The regression objective then is to estimate the regression parameters from given data D¼{(
, d
)}, where x (i) and t (i) are the vector of gene expression values and the censored survival time for patient i, respectively, and d (i) is an indicator variable that is 1 when censoring acts on the survival time for patient i, and hence it is only known that the true survival time is greater than t (i) , and 0 if t (i) is an actual survival time. Under the condition of random censoring over time and under mild independence requirements (independence of the distinct censoring times and independence of the censoring process from the survival times and from ), the maximum likelihood solution to the regression problem is the parameter vector maximizing 
However, given that one has far more genes than patients, many solutions exist that fit the training data very well, and predictions made using a vector obtained by maximizing Equation (2) are usually not very good, since the predictor tends to overfit the data.
Automatic relevance determination
The Bayesian approach to classification and regression problems assumes that we are given a hypothesis space of functions h mapping from the covariates x to survival time t and containing the true hypothesis h true underlying the data. For the Cox regression model, this hypothesis space is parameterized by , and one could use, for predictions, the expected value
where f(t j x, ) is the probability density function of the Cox regression model, and is easily derived from Equation (1). The probability of any given hypothesis h , given the data D, can then be calculated according to Bayes' theorem as
As prior distribution p() on the regression parameters , we chose independent, mean-zero normal distributions with variances s 2 i on the components i , implying the assumption that the parameters i should not become too large. Choosing the mean zero corresponds to the assumption that most genes will not be related to survival, and thus their weights i should be close to zero. Only if the data warrant it, will the weights be driven away from zero. The parameters s i control the width of the distributions over the i . Since we expect very few of the microarray features to be linked to survival, for most features, the distribution p( i ) should be strongly peaked around zero.
The proper Bayesian approach to deal with unknown parameters such as s i is to specify a prior distribution over them, and then integrate out the parameters. That way, one can avoid having to specify one fixed value for the hyperparameters s i , which will normally be difficult to estimate, but instead just has to provide a general distribution, which is often much easier to do.
The expectation of a 'sparse hypothesis' h , with only a small subset of the genes significantly affecting survival, can be modelled using independent gamma distributions on the s i ,
where GðrÞ :¼ R 1 0 t rÀ1 e Àt dt is the Gamma function, and a and r are positive parameters controlling the shape of the distribution. Note that, to avoid the case s i ¼ 0, only values of r > 1 should be used. Figure 1 shows the resulting prior
for the two-dimensional case. The plot clearly shows how the prior favors solutions with most of the weights in the proximity of zero, thus automatically selecting only a small subset of the genes for regression.
Models with similar hierarchical prior distributions have been introduced by and Mackay (1992) in the context of neural networks, and have become popular as 'Automatic Relevance Determination' models.
Inserting Equations (2) and (6) into (4), taking the negative logarithm and dropping terms independent of , maximization of p( jD) is equivalent to minimizing
where Z j ðÞ :¼ l 0 t ðjÞ e x ðjÞ and where, for simplicity, we have assumed that the baseline hazard l 0 (t) ¼: l 0 is constant with respect to time t. The first term in Equation (7) comes from the prior distribution, integrating over the normal distribution over the weights and the gamma distribution over the standard deviation s, the second term comes from Equation (2) by inserting the survivor and density functions of the Cox regression model. Equation (7) can be minimized with respect to using conjugate gradient descent, see Supplementary Material for details on algorithm and running time. The obtained parameter can then be used for predictions on new patients with Equation (3), and the magnitudes of the weights provide information on the relevance of individual genes. We have termed this approach CASPAR, for CAncer Survival Prediction using Automatic Relevance determination.
Time-dependent ROC analysis
Owing to censoring, prediction errors cannot be calculated directly. Therefore, for evaluation of our method, we will use time-dependent receiver operator characteristic (ROC) analysis, as suggested by Heagerty et al. (2000) . Let c i (t) be a {0, 1}-variable, indicating whether patient i has had an event prior to or at time t (c i (t) ¼ 1) or not (c i (t) ¼ 0). Furthermore, let h (x) be the predicted survival time of a patient with gene expression values x. One then defines the time dependent sensitivity and specificity as sensitivityðc‚ t j h ðxÞÞ ¼ Pfh ðxÞ < c j cðtÞ¼1gð 8Þ specificityðc‚ t j h ðxÞÞ ¼ Pfh ðxÞ!c j cðtÞ¼0g:
Hence, the objective is taken to be the identification of the short survivors, and sensitivity is defined as the probability of correctly identifying a short survivor (true positive), whereas specificity is the probability of correctly identifying a long survivor (true negative). c is a parameter that can be used to control the trade-off between sensitivity and specificity. Using these definitions, time-dependent ROC curves can be drawn by varying c and plotting sensitivity against specificity. ROC curves can be summarized by computing the area under the ROC curve (AUC), and the AUC can then be plotted with respect to time.
RESULTS

Caspar correctly predicts overall survival in lung cancer
We applied CASPAR to the publicly available dataset from Bhattacharjee et al. (2001) on LC. Details on the data and on data preprocessing are given in Materials and Methods. Since the dataset contains only 125 patient samples, we used leave-one-out crossvalidation to test our method. We attempted to address CASPAR's performance with respect to three aspects: First, the accuracy of predictions of survival on the overall dataset was analyzed. Then, we compared results with surgical staging. Finally, CASPAR was used to subdivide stage I patients, for which such a subdivision is particularly desirable.
Training was carried out using leave-one-out crossvalidation. Parameters used in training were a ¼ 5 and r ¼ 1.001, and constant baseline hazard l 0 ¼ 0.19. Prediction results were collected for the 125 crossvalidation runs, the data were then split in short-( 3.5 years) and long-term (>3.5 years) survivors according to the predictions made. The median survival time of patients in the study is 3.5 years. Figure 2 (left plot) shows the resulting survivor functions for the two subgroups. A logrank test of equality yields a P-value of 0.057. Figure 3 shows the ROC curve for 2 years (left), and the AUC for the time interval from 0 to 10 years.
We compared predictions of CASPAR with surgical pathological staging. Staging information is provided on 111 of the 125 patients in this study. The median survival times of stage IA and stage IB patients in the study are 7.5 and 6 years, respectively. This distinction is reflected by our results, predicting an average survival time of 8.7 and 8 years for patients in these stages, respectively. The true median survival time for stage II patients in the study is 2.2 years, our method predicts an average overall survival of 4.9 years for stage 2 patients, which is significanty lower than the predicted 8.3 years for stage I patients. Only 13 patients in the study fall into stages III and IV, with a median survival of just 1.3 years. The number of cases here is too small for training, accordingly, patients from this group are not recognized well by the method.
For the physician, it is of great interest to have a predictor of survival for stage I adenocarcinoma patients. Stage I patients are normally treated by surgical resection of their tumor, and do not receive any additional chemotherapy or radiation therapy. Although patients diagnosed with stage I adenocarcinoma have a 5 yearsurvival rate of 63%, nearly 35% will relapse after surgical resection, thus portending a poor prognosis (Chen et al., 2003) . An identification of these high-risk patients with resectable early-stage disease would allow therapeutic intervention on these patients, possibly leading to increased survival among this group. Figure 2 (right plot) shows the survival curves for stage I patients predicted to survive >5 years versus stage I patients predicted to survive 5 years (P ¼ 0.13, n ¼ 75). As can clearly be seen, CASPAR can subdivide stage I patients further, providing a meaningfull classification in low-and high-risk stage I patients.
Summarizing the above findings, CASPAR clearly distinguishes stage I and stage II patients based on their gene expression levels. These patients benefit most from a prognosis of their disease, since several treatment options exist and could be chosen from based on CASPAR: predicting cancer survival rates an assessment of disease aggressiveness. Overall, however, a larger number of patients in the study would clearly be desirable and could yield improved results.
Validation of survival predictions of CASPAR in DLBCL
As a second test, we applied CASPAR to the publicly available dataset on DLBCL published by Rosenwald et al. (2002) . This dataset contains almost twice the number of samples available in the LC study. The data were preprocessed as described in Materials and Methods. CASPAR was trained on the training data only, with a ¼ 5 and r ¼ 1.001, and constant baseline hazard l 0 ¼ 0.1, and then used to predict the expected survival time according to Equation (3) for each patient in the validation set. Predictions made for survival using CASPAR were used to split patients in short ( 5 years) and long term survivors (>5 years), and the survivor functions shown in Figure 4 were calculated based on the true survival time for the two subgroups separately. The threshold of 5 years was chosen since this is the median overall survival time in DLBCL. A logrank test of the null-hypothesis H 0 of equality of the two survival curves was made, it yields a P-value of 0.0000342, which is highly significant for rejecting H 0 , indicating that CASPAR successfully separated short from long-term survivors.
ROC analysis reveals high performance of CASPAR Figure 5 shows the time-dependent ROC curve for time t ¼ 5 years for CASPAR predictions on DLBCL, and the area under the curve with respect to changing time. The plot shows that the AUC is $0.772 for all t (recall that higher AUC values are indicative of better performance). As a comparison, published AUC plots for partial Cox regression models, involving repeated least squares fitting of residuals and Cox regression fitting, on the same dataset we used in our work and with the same split of the data in training and validation subsets. For the best model reported in their manuscript, the AUC is between 0.62 and 0.67, depending on time t. Lossos et al. (2004) derive the 6-gene predictor score
Using this predictor on the Rosenwald data, the AUC is $0.6. The dashed lines in Figure 5 correspond to results obtained using the Lossos et al. (2004) predictor.
CASPAR enables subdivision of grous within the IPI in DLBCL The IPI is a clinical scoring system widely used for predicting outcome in DLBCL. It is based on a variety of factors, including patient age, tumor stage, performance status, number of extranodal sites of involvement and serum LDH level (Gascoyne, 2002) . The IPI scores patients on a scale from 0 to 5, with those having a low IPI score (0,1) demonstrating 5 year overall survival rates of 73% versus patients with high IPI scores (4, 5) with only 26% 5 year overall survival. Importantly, in most studies, almost half of the patients fall into the intermediate-risk categories (IPI scores of 2-3), whose survival characteristics mimic those of DLBCL overall, with $50% of the patients surviving beyond 5 years (Gascoyne, 2002) . It is thus of high interest to obtain an independent predictor that is able to further subdivide patients in the medium risk segment. Figure 6 shows separate survival curves for the patients in the low (left) and medium risk (right) groups as determined by CASPAR on the validation dataset. A logrank test of the null hypothesis of equality of the two curves in each plot was made, giving P-values of 0.0135 for low IPI patients and 0.0000747 for medium IPI patients. As clearly demonstrated, CASPAR further subdivides patients from the same IPI group, thereby providing additional information, which could be used clinically as a complementary staging strategy to the IPI.
We also performed the inverse test. When calculating survival time predictions using CASPAR, patients are confirmed to belong to different risk groups, in accordance with the IPI. Patients belonging to the group with low IPI score (0, 1) are predicted to have average survival time of 13.2 years, patients belonging to the medium risk groups (IPI 2, 3) show average predicted survival time of 9.2 years, whereas patients belonging to the high risk groups (IPI 4, 5) are predicted to have an average survival time of 6.7 years. Note that the values reported here are average survival times, not median survival, and hence cannot be related directly to the Kaplan-Meier plots in Figures 4 and 6.
Performance of CASPAR is independent of sample splitting To further validate the results, training was repeated 50 times, with the data split differently and randomly in training and validation subsets in each run. A total of 45 runs show good separation of the Kaplan-Meier curves for the predicted short ( 5 years) and longterm (>5 years) survivors on the validation dataset, with an achieved CASPAR: predicting cancer survival rates significance level of 10%. A total of 43 runs are significant at the 5% significance level, and 27 runs even at the 1% significance level. Only one of the 50 runs fails at the 25% significance level, with a P-value of 0.453. This run is characterized (randomly) by an unequal split in training and validation data, the validation data containing a high proportion of short survivors and no uncensored long-term survivors, and the training data containing few short-and many long-term survivors.
Overall, the average AUC value over all 50 runs and all timepoints t is 0.64.
Direct association of biologically relevant genes to survival
Interestingly, different genes receive high weights in the 50 runs. This shows a typical problem in microarray data analysis, where frequently different genes are identified in different studies (compare Table 1 ). One possible explanation for this observation might be the high correlation between genes measured. O' Neill and Song (2003) pointed out that the level of information redundancy in large gene expression assays is unknown, and that different, mutually exclusive gene sets may be equally useful predictors. This point is confirmed by Alon et al. (1999) , who discarded the 1500 genes indicated by cluster analysis as most discriminatory in their study of colon cancer, and, upon reclustering, found their diagnosis unimpaired. Hence, if several features are highly correlated, each one of them could in principle function as part of a predictor. The prior distribution p() used on the weights in our approach, however, will ensure that redundant information is removed from the predictor. Which feature is chosen in the predictor will depend on effects such as the randomness involved in splitting the data in training and validation subsets.
Correlated genes in the data can be identified by clustering. For this purpose, genes were clustered using standard hierarchical clustering, with Pearson correlation as similarity measure. Clustering was continued until the similarity between joined clusters dropped below 0.5. At this point, the 7399 microarray features are clustered in 2366 different clusters. Table 1 shows genes that were reported in several studies [compare the summary in ], and the respective clusters they were assigned to by the hierarchical clustering algorithm.
A more detailed analysis of the genes identified in the 50 repetitive runs reveals that many of those genes are highly correlated to genes listed in Table 1 . High weights are given to genes from cluster 1525 (containing CD38), 4743 (containing HLA-DQA1 and HLA-DRA), 4939 (BCL2, CCND2, CD44, CFLAR, SLA, IRF4, PDE4B), cluster 4990 (containing FN1, SCYA3, ICAM1/ CD54, PRDM1, SLAM, PLAU), cluster 5000 (containing genes BCL6, PAX5, Ki-67, BIRC5, WASPIP, PMS1, NPM3, MYC, EEF1A1L4) and cluster 5029 (CD10, HGAL, MYBL1/A-MYB, PIK3CG).
Several additional genes are reported by CASPAR. WASF3 receives high weights in 35 runs, elevated expression of this gene is predicted to correlate negatively with survival. A total of 29 runs show an association with BMP6. BMP6 is one of the main prognostic genes identified by Rosenwald et al. (2002) in their study, however, Lossos et al. (2004) later excluded BMP6 from their meta analysis, arguing that the gene was not associated with survival in independent data analyses. Our results indicate that expression of BMP6 correlates negatively with survival. TP63 receives high weights in 21 runs. Expression of this gene is predicted to correlate positively with prolonged survival. Even though TP63 has been reported to be associated with DLBCL before (Akahoshi et al., 2003) , it is not as prominent a candidate as other genes, and may deserve further attention. RAFTLIN receives high weights in 29 runs, MNDA in 18 runs, TCF7 in 14 runs and LC_31372 receives high weights in 12 runs. Elevated expression of all of these genes is predicted to correlate with prolonged survival.
Taken together, CASPAR yields good predictions of overall survival on DLBCL, with high rates of sensitivity and specificity. It complements the IPI, and can refine predictions made using the IPI. Furthermore, CASPAR identifies biologically relevant genes and points to several new candidates related to survival.
DISCUSSION
In this paper, we have presented CASPAR, a new method to correlate gene expression data with survival, based on a combination of the Cox regression model with a Bayesian automatic relevance determination (ARD) approach. The method automatically weights genes with respect to their relevance concerning patient outcome, while penalizing models with too many genes, thus encompassing dimension reduction and regression in one single step. The method uses a hierarchical prior distribution on the regression parameters, specifically designed to deal with the high dimensionality, low sample number setting characteristic of microarray studies. This allows the application of a multivariate Cox regression model on datasets with several hundred to several thousand genes, with only a L. Kaderali et al. small number of patients compared with the number of genes available, and avoids the problem of loosing relevant information in a separate dimension reduction step carried out before the actual regression.
The price paid for the ability to process high dimensional data are assumptions to be made through the prior distribution on the regression parameters . While p() enables the method to control the curse of dimensionality, it biases the predictor towards solutions where only few of the genes have large weights, and where i do not become too large. Through the choice of parameters for the prior, one trades variance of the predictions made against bias of the predictor. The strength of prior required depends on the number of genes and on the number of samples available for training, and needs to be chosen carefully. If the prior is too strong, it will determine results. On the other hand, if the prior is too weak, results will be random owing to the high dimensionality of the data. The higher the dimensionality of the data, the stronger the prior assumptions required for the parameters . Careful engineering is required for the choice of parameters a and r controlling this trade-off.
Many studies of gene expression data in cancer cluster patient samples together based on their genetic profiles, and associate clusters identified with survival differences in retrospect. Characteristic genes for each cluster are then sought, and used to classify new patients in one of the cluster groups. While this clearly is a valid approach, its disadvantage lies in the fact the the clustering process itself may be dominated by genes with large variability, that are actually unrelated to survival. Our approach directly tries to identify genes and combinations of genes correlated to survival on the full dataset, which are then used to assign a new patient to one of several risk classes directly based on predicted survival time distributions.
We demonstrated the utility of our method on two publicly available datasets. On both datasets, CASPAR is able to separate long from short survivors, even though separation is significantly better in the larger dataset from the DLBCL study. One possible explanation is the lower sample number especially in those stage groups (stage III, n ¼ 10) in the LC study that did not perform well. Alternatively, with increasing stage of disease, one might also consider that gene expression profiles in LC might not be as informative for survival as previously suggested. This might also be explained by the biology of the disease. While stage III lung cancer is characterized by extrapulmonary extension of the tumor without evidence of distant metastasis, stage IV tumors are defined by distant metastasis. This change in biology is in fact correlated with differences in survival (Etzioni et al., 2003) and as previously described also with changes in gene expression (Ramaswamy et al., 2003) . Our correct predictions of short survival of stage IV is therefore in line with earlier observations. Certainly, these important issues need to be addressed in future clinical studies in lung cancer.
The finding that many of the genes in the DLBCL data are strongly correlated suggests to cluster the data first, and then carry out the gradient descent training. This brings the additional advantage that the gradient descent can be carried out in a lowerdimensional space. However, our results indicate that prediction results are actually worse when the data are clustered before training (data not shown). Apparently, useful information is getting lost in the clustering process. At the same time, the analysis of the 50 separate runs with the data split differently in training and validation subsets indicates that there is a high degree of correlation between different genes, and that clustering may be useful to avoid correlated genes. This may appear contradictory at first sight. The Table 1 . Genes identified as being associated with survival in DLBCL in several studies in the literature [compare , sorted according to clusters they fall into after hierarchical clustering problem is that it is not clear when to stop clustering. If clustering is interrupted too early, there will still be a high degree of redundancy in the data. On the other hand, if the data are clustered too long, much useful information may get lost. This is a delicate trade-off. We therefore suggest to use CASPAR on the full data, and carry out clustering in retrospect to find correlations. In both, the lymphoma and the lung cancer study, our approach is able to refine predictions made using clinical scores widely used, particularly on low-and medium-risk patients in DLBCL and on stage I patients in lung adenocarcinoma. These groups benefit particularly from such refined predictions, since they are relatively heterogeneous with respect to survival. In DLBCL, survival characteristics of patients with medium IPI score (2, 3) mimic those of DLBCL overall, with $50% of patients dying in the first 5 years after diagnosis. In LC, nearly $35% of stage I patients relapse after surgical resection. Using predictions made by the approach presented, these patients may be identified and could benefit from more adjuvant therapies.
Conflict of Interest: none declared.
Individualized Predictions of Survival Time Distributions from Gene Expression Data Using a Bayesian MCMC Approach
Lars Kaderali
German Cancer Research Center (dkfz), Theoretical Bioinformatics, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany l.kaderali@dkfz-heidelberg.de
Abstract. It has previously been demonstrated that gene expression data correlate with event-free and overall survival in several cancers. A number of methods exist that assign patients to different risk classes based on expression profiles of their tumor. However, predictions of actual survival times in years for the individual patient, together with confidence intervals on the predictions made, would provide a far more detailed view, and could aid the clinician considerably in evaluating different treatment options. Similarly, a method able to make such predictions could be analyzed to infer knowledge about the relevant disease genes, hinting at potential disease pathways and pointing to relevant targets for drug design. Here too, confidences on the relevance values for the individual genes would be useful to have. Our algorithm to tackle these questions builds on a hierarchical Bayesian approach, combining a Cox regression model with a hierarchical prior distribution on the regression parameters for feature selection. This prior enables the method to efficiently deal with the low sample number, high dimensionality setting characteristic of microarray datasets. We then sample from the posterior distribution over a patients survival time, given gene expression measurements and training data. This enables us to make statements such as "with probability 0.6, the patient will survive between 3 and 4 years". A similar approach is used to compute relevance values with confidence intervals for the individual genes measured.
The method is evaluated on a simulated dataset, showing feasibility of the approach. We then apply the algorithm to a publicly available dataset on diffuse large B-cell lymphoma, a cancer of the lymphocytes, and demonstrate that it successfully predicts survival times and survival time distributions for the individual patient.
Introduction
Gene expression profiles have been shown to correlate with survival in several cancers [1, 13] . One important goal is the development of new tools to diagnose cancer [5] and to predict treatment response and survival based on expression profiles [14, 12] . A classification of patients in different risk classes has been S. Hochreiter and R. Wagner (Eds.): BIRD 2007 , LNBI 4414, pp. 77-89, 2007 . c Springer-Verlag Berlin Heidelberg 2007 demonstrated to be a first step [12] , and can aid the clinician in evaluating different treatment options. However, predicting actual survival times together with confidence intervals on the predictions would be a valuable progress. Furthermore, an analysis of such a predictor could hint at relevant genes that correlate with survival, which may provide new information on pathogenesis and ethiology, and may further aid in the elucidation of disease pathways and the search for novel targets for drug design.
One of the main statistical problems in gene expression data analysis stems from the large number of genes measured simultaneously, typically in the range of several thousands to tens of thousands, while usually only a few dozen to several hundred patients are available, even in the larger studies. This causes problems with multiple testing in hypothesis testing approaches, and yields regression models with thousands of unknowns but only a small number of data points to estimate model parameters, and is a severe limitation [11] . For this reason, dimension reduction methods such as clustering or principal components analysis are typically carried out prior to further analysis. Unfortunately, criteria used in dimension reduction are often unrelated to the prediction model used to analyse the data later and to survival, and may remove relevant genes.
By combining dimension reduction and parameter estimation for regression parameters into one single step, one can avoid the problems stemming from a separate dimension reduction. Feature selection can be combined into the regression using a Bayesian approach, penalizing overly complex models using a special feature selection prior on the regression parameters. On can then maximize the posterior, and use the resulting regression parameters for predictions on new patients [7] .
However, from a theoretical point of view, instead of using the maximum a-posteriori regression parameters for predictions, one should average over all possible regression parameter values, weighting each with its probability when making predictions. Let D be the training data given, let x be the vector of gene expression values measured for a new patient, and let t be the patient's survival time. Then, instead of maximizing the posterior p(θ|D) and using the resulting vector θ to predict, for example, the mean of a distribution p(t|x,θ), predictions ought to be based on the distribution
where the integration is over the full parameter space Ω. Computationally, this requires an integration over the full (and potentially very high dimensional) parameter space, and is far more involved than a simple maximization of the posterior p(θ|D).
In this report, we evaluate equation (1) using a Markov Chain Monte Carlo (MCMC) approach. This allows us to sample survival times directly from the distribution p(t|x, D), which are used to compute means and variances over survival times for the individual patient. The distribution over predicted survival times can be visualized, providing far more information than just a mere predicted risk class or a single survival time in years. In addition, we demonstrate sampling from the posterior distribution p(θ|D), which provides relevance values with confidence intervals for the distinct gene expression values measured, revealing relevant survival related genes.
After a presentation of the method, we show its application to a simulated dataset first, and then present results on a publicly available clinical dataset on diffuse large B-cell lymphoma, a cancer of the white blood cells.
Approach
The Cox Regression Model
Let x ∈ IR n be the vector of gene expression measurements for a given patient of interest, where n is the number of genes measured, and let T be a random variable corresponding to the survival time of the patient. The Cox regression model [3] postulates that the risk of failure in the next small time interval ∆t, given survival until t, is given by
where θ ∈ IR n is a vector of regression parameters, and λ 0 (t) is an arbitrary baseline hazard function describing the hazard when x =0 .G i v e nx and θ, the hazard completely specifies the survivor function F (t)=P {T ≥ t} and the probability density function f (t)=−dF (t)/dt.
Survival data in clinical studies is usually right-censored, i.e., for some patients, only a lower bound on the survival time is known. Under the conditions of random censoring over time, independence of the censoring times for distinct patients from one another, and independence of the censoring process from x and θ, the maximum likelihood solution to the regression problem is the parameter vector θ maximizing
where m is the number of patients in the clinical study and x (j) and t (j) are the vector of the gene expression measurements for patient j and the patients survival time or censoring time, respectively. The indicator variable δ (j) is 1 if t (j) is censored, and 0 otherwise.
Bayesian Extension of the Cox Model
In the setting where one measures far more genes than one has patients in the study, n> >m , typical of microarray measurements, the optimization problem of maximizing equation (3) with respect to θ is underdetermined. A predictor b a s e do nav e c t o rθ obtained from such a maximization will usually overfit the data. This problem can be controlled using Bayesian regularization.
The posterior distribution over the regression parameters θ given the training data D is given by
Here, p(D|θ) is given by the likelihood (3), according to the Cox regression model. p(θ) is a prior distribution over the regression parameters θ, reflecting our subjective prior beliefs about the parameters, and p(D)= p(D|θ)p(θ) dθ.
The central assumption we make at this point is that most of the gene expression measurements x i for given genes i are not related to survival. This is modeled using independent mean-zero normal distributions on the components θ i of the parameter vector θ. Furthermore, we assume that most of the normal distributions are strongly peaked around zero, by using independent gamma distributions on the standard deviations of the normal distributions on the regression parmameters. Thus, the prior distribution p(θ) on the regression parameters is given by
where a and r are scale and shape parameters of the gamma distribution, and Γ (·) is the gamma function. Figure 1 shows the resulting prior for the twodimensional case. The plot clearly shows how the prior favours solutions with most of the weights θ i in the proximity of zero, thus penalizing models with a large number of relevant genes. One can now maximize the posterior (4) and use the resulting weights θ to make predictions for new cases [7] . However, from a theoretical point of view, one should not focus on just one single underlying vector of regression parameters θ. In fact, the distribution p(θ|D) may have multiple modes. To determine the relevance of individual genes, the full distribution p(θ|D) should be considered. Similarly, predictions of the survival time t for a new patient with gene expression values x, given the training data D, should be based on the full distribution
Mean and variance of the distributions p(θ|D)a n dp(t|x, D) can then be used to asses the relevance of individual gene expression measurements and to make survival time predictions for newly diagnosed patients, respectively.
Hybrid Monte Carlo Algorithm
Unfortunately, the integrals required to calculate means and variances of equations (4) and (6) are not analytically tractable. In addition, the integration in (6) over θ has to be carried out in a very high dimensional space, depending on the number of gene expression values measured. Computationally, this is a challenging problem. We propose to use the Hybrid Monte Carlo (HMC) algorithm for this purpose. The algorithm was developed by [4] for problems arising in quantum chromodynamics, good reviews can be found in [10] and [2] . HMC samples points from a given multi-dimensional distribution π(ν), expressed in terms of a potential energy function E(ν)=− ln π(ν), by introducing momentum variables ρ =(ρ 1 , ..., ρ n ) with associated kinetic energy K(ρ), and iteratively sampling for the momentum variables from K(ρ) and following the Hamiltonian dynamics of the system in time. Doing so, the algorithm generates a sequence of points distributed according to π(ν). Moments of the distribution π(ν)c a nt h e nb e estimated from the samples drawn. In our application, estimates derived from p(θ|D) will then provide some information on the relevance of individual genes.
The optimum survival time prediction y for a given patient depends on the error function err(t, t true ) used to measure the error of predicting a survival time t w h e nt h et r u es u r v i v a lt i m ei st true . When the squared error function err(t, t true )=(t true − t) 2 is used, it is optimal to predict the mean
This expression can be approximated in two steps:
). This is easily done for the exponential distribution used in the Cox regression model using rejection sampling.
These two steps are repeated a large number of times, say for k =1, ..., N ,a n d (7) is then approximated as
Similarly, the samples drawn can be used to compute the variance of p(t|x, D).
3R e s u l t s
As a proof of principle, we applied the approach presented to a simple simulated dataset first, where the true underlying processes determining survival are known. Then, the method was applied to a publicly available dataset on diffuse large B-cell lymphoma (DLBCL), a cancer of the B-lymphocytes.
Simulated Data
Data Simulation: Gene expression levels and survival times were simulated for 240 patients and 7400 genes, using the Cox model, with constant baseline hazard λ 0 (t)=0.18. It was assumed that only the first gene x
1 has an influence on the survival time t (j) of patient j, all other genes were assumed not to be correlated to survival. The expression level x (j) i was drawn from a normal distribution with mean zero and standard deviation 0.5 for all genes i =2, ..., 7400 and all patients j =1, ..., 240. The "relevant" gene x (j) 1 was either drawn from a normal distribution with mean -0.6 and standard deviation 0.5, or from a normal distribution with mean +0.6 and standard deviation 0.5, corresponding to two assumed subclasses with different survival characteristics. Patients were randomly assigned to one of these two classes. Survival times were then simulated by sampling from the Cox model. Each patient was subject to random, uniform censoring over the time interval [0, 10] .
Gene relevances θ: The data was split in training and validation subsets, with 2/3 of the patients in the training subset, and 1/3 reserved for validation. Parameters for the prior distribution over the regression parameters θ were set to r =1 .6a n da = 40. HMC sampling was started several times with different starting points, with similar results. 500 initial points of the Markov chain were discarded, 2500 points were sampled from p(θ|D) and used to compute mean and variance. Gene x 1 is correctly identified as correlated with survival, with mean E[θ 1 ]=0.7274 and standard deviation 0.0949. All other weights θ 2 , ..., θ 7400 have means smaller than 0.0025 and standard deviation smaller than 0.01. Figure 2 shows the projection of the points θ sampled onto the first two dimensions θ 1 and θ 2 . Survival time predictions: Survival time predictions for the validation samples were then made as described. Figure 3 (left) shows the true survivor functions F (t) for the groups predicted to survive up to and including 5 years, and longer than 5 years in the validation subset. Shown along with the survivor functions are two standard deviation error bars on the estimates. A logrank test of the null hypothesis of equality of the survivor functions gives a p-value of 1.7 × 10 −6 (n = 80), which is highly significant for rejecting the null hypothesis. Time dependent receiver operator characteristic [6] curves are useful to evaluate the performance of a predictive algorithm for censored survival times. ROC curves plot all achievable combinations of sensitivity over specificity for a given classifier on two-class classification problems. In the context of survival analysis, a threshold t on the survival time is used to distinguish short from long survivors. The area under the ROC curves (the AUC) can then be plotted for different threshold times t. This value AU C(t) will be in the interval [0, 1] , with larger values indicative of better performance of the predictor, and a value of 0.5e q u i v a l e n tt og u e s s i n gas u r v i v a lt i m e . Figure 3 (right) plots the area under the ROC curve for different thresholdtimes t in the interval [0, 20] , confirming that the sampling algorithm can be used to successfully predict survival times on the simulated dataset.
Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is a cancer of the lymphocytes, a type of white blood cell. It is the most common type of lymphoma in adults, and can be cured by anthracycline-based chemotherapy in only 35 to 40 percent of patients, the remainder ultimately succumbing to the disease. The dataset used was collected by [12] , it consists of 7,399 gene expression values measured in 240 patients, using the lymphochip assay.
The data was preprocessed to reduce dimensionality prior to analysis with the Markov Chain. Several runs on the full dataset were conducted first, but no sufficient convergence of the chains was achieved in acceptable running times. Genes with more than 40 percent missing values or with variance less than 0.45 were removed. Genes were then clustered using hierarchical clustering, with Pearson's correlation coefficient as similarity measure. Clusters were represented by their means. Clustering was interrupted when similarity dropped below 0.5 for the first time, at which point the genes were clustered in 1582 distinct clusters. Finally, the data was normalized such that each gene had mean zero and variance one. Patients were then split in training (n = 160) and validation (n = 80) subsets, using the same split as in the original Rosenwald publication.
Gene relevances θ: 11, 000 points θ (k) were drawn from the distribution p(θ|D), using the hybrid Monte Carlo algorithm. Parameters used in the prior distribution p(θ)w e r ea =3 0a n dr =1 .6, and constant baseline hazard λ 0 (t)=0 .18. The first 1, 000 steps of the Markov Chain were discarded, to allow the chain to converge to its stationary distribution. To check for convergence of the chain, different random starting points were used in different runs, with very similar results.
The genes receiving weights most strongly corresponding to short survival in the runs conducted are LC 25054, E1AF, ETV5, DKFZp586L141, SLCO4A1, MEF2C, CAC-1 and a few others. Genes most strongly associated with long survival are RAFTLIN, RGS16, MMP1, several MHC genes (including DP, DG, DR and DM alpha and beta genes), CD9, TP63, CD47, and a few others. Several of these genes have previously been reported, a biological validation is under way and will be published elsewhere.
Survival time predictions:
Survival times for the patients in the validation subset were predicted using the two-step-procedure presented. the survivor functions estimated from the true survival times, for the subsets of patients in the validation subset predicted to live short (≤ 5 years) versus long (> 5 years), along with two standard deviation error bars on the estimate. A logrank test of the null-hypothesis of equality of the survivor functions of the two subgroups yields a p-value of 0.01195 (n = 80). Figure 4 shows the area under the time-dependent ROC curves of the survival time predictions, plotted over time.
One of the major advantages of the Bayesian approach presented is the ability of the method to access the full distribution p(t|x, D). This enables us to compute variances on the predictions made, and makes it possible to visualize the distribution over survival times for the individual patient, providing significantly more information than is available from "classical" regression methods. Figure 5 illustrates this clearly. The plot shows histograms of the predicted survival times for selected patients, generated from the survival time predictions made. Shown are survival time predictions for two representative patients, patient 18 and patient 21.
Patient 18 has a true survival time of only 0.9 years, even though the patient has a good prognosis according to clinical staging using the International Prognostic Index (IPI). The prediction made using the approach presented is very unfavorable, with a mean predicted survival time of merely 1.3 years, and a standard deviation over predictions of 1.4 years. The empirical distribution over survival time predictions is shown in Figure 5 (left), and reflects this unfavorable outcome. The low standard deviation over the predictions indicates a strong confidence in the predictions made, and this distribution would have been an early warning that the patient may be at higher risk than indicated by clinical staging.
Patient 21 is a long survivor, the true survival time is not known. The patient was still alive at 6.4 years, at which time he dropped out of the study. Figure 5 (right) shows relative frequencies of predicted survival times for this patient, the mean of the predictions made is 4.6 years, however, the standard deviation is 5.4 years, indicating less certainty in the predictions made for this patient. The patient falls into the medium risk segment of the International Prognostic Index (IPI), which coincides with the distribution over predicted survival times made by our approach.
Discussion
We have analyzed the performance of the method presented on a simulated and a real-world dataset. Results on the simulated data show that the method is able to automatically recognize relevant genes and make predictions of survival directly on high dimensional data, without additional dimension reduction steps. In addition, variances for the survival times predicted can be computed, yielding significantly more information to a clinician than a mere prediction of a risk class. The Kaplan-Meier plots and the receiver operator characteristics analysis in Figure 3 confirm that the method developed has successfully learned the underlying mechanisms influencing survival from the data.
Obviously, an analysis of a real-world dataset is more complex than processing the simulated data. The level of noise in gene expression measurements is unknown, and relevant survival related factors are likely not available. The number of relevant genes affecting survival in DLBCL is unknown, as is the level of redundancy in the data. Last but not least, the Cox regression model used may not appropriately reflect the distribution over survival times, and certainly is a crude approximation to the true distribution at best.
For running time reasons, it turned out to be necessary to carry out some dimension reduction on the DLBCL data prior to analysis by the method presented in this article. Several runs of the Hybrid Monte Carlo algorithm were conducted on the full dataset first, each requiring approximately three days on the machine used (Pentium IV, 3 GHz) to sample 10, 000 points from the distribution p(θ|D). However, during these 10, 000 steps, no sufficient convergence of the Markov Chains was achieved, and much longer sampling appears to be necessary. This is likely due to the high redundancy of microarray gene expression measurements, and correspondingly multiple modes of the distribution p(θ|D). For this reason, the data was clustered with respect to the genes, reducing dataset dimensionality and removing redundant information. This contrasts to the maximum a-posteriori approach we have previously presented, where the analysis could be carried out on the full data without clustering the genes first [7] .
This additional clustering step necessary to reduce dataset dimensionality, and the complications arising from it, may explain the slightly inferior results of the Markov Chain Monte Carlo approach presented when compared to the maximum-a-posteriori (MAP) approach laid out in [7] . From a theoretical point of view, the MCMC approach should be favored, since it makes use of the full distribution p(θ|D) for predictions, and not just the single parameter vector θ * maximizing p(θ|D). In addition, confidence intervals are readily available in the MCMC approach, whereas they cannot directly be computed for the MAP solution since the integrals involved are not analytically tractable, and additional approximations and assumptions would be necessary.
The predictive performance of the MCMC approach is comparable to other, recently published results. For example, [8] have recently published AUC plots for partial Cox regression models, involving repeated least squares fitting of residuals and Cox regression fitting, on the same dataset we used, and report AUC values between 0.62 and 0.67 for the best model in their publication, depending on time t. Similarly, [9] have presented a 6-gene predictor score for survival in DLBCL, applying their method to the Rosenwald data, the area under the time dependent ROC curves is approximately 0.6 for all timepoints t. Results of the MCMC approach we present yields comparable results, but in addition, can provide confidences on the predictions made.
5C o n c l u s i o n
From the methodological point of view, this work raises two questions that may deserve further evaluation. Our comparison of results of the MCMC approach and the MAP approach to making predictions indicates that relevant information may get lost in the clustering process. This is an interesting observation in so far that most approaches in use for survival time predictions from gene expression data today make use of extensive dimension reduction steps prior to carrying out the actual data analysis. Such steps are often based on arbitrary cutoff levels determining more or less directly how many genes are used for the prediction. The choice of such cutoff levels is often a difficult problem, but results may depend significantly on them. If too many genes are used, a predictor may be prone to overfitting, and may struggle with multiple modes and redundant information in the data. On the other hand, if too much data reduction is carried out, relevant information may be thrown away. The proper tradeoff is a delicate balance, and difficult to achieve.
The second question raised directly relates to the degree of redundancy in gene expression measurements. Given that some of the genes measured on microarrays are highly correlated, and given the analysis problems stemming from high dimensional data with only few samples in clinical studies, clearly larger studies with more patients and more sophisticated analysis methods are highly desirable. The prior distribution used over the regression parameters in this work aims at dealing with this problem by favoring solutions with only few relevant genes. At the same time, however, a more thorough study of correlation between genes may be useful to guide the design of future clinical studies, and algorithms should exploit the correlation structure in the data. After all, what is the point of measuring expression values of more and more genes, if all we can do with the additional information is to come up with more and more sophisticated methods to reduce dataset dimensionality again?
To summarize, we have presented a novel, Markov-Chain based approach to predict survival times in years and months, together with confidences, from gene expression data. The method provides feedback on the relevance of individual genes by weighting the gene expression measurements, and it considers the full distribution p(θ|D) over the weights when making predictions, instead of merely using the single vector θ * maximizing p(θ|D). By computing first and second order moments of the distribution p(θ|D), certainties in the gene relevances can be given.
Similarly, the full distribution p(t|x, D) is evaluated when making survival time predictions for a new patient x, given the training data D. The method allows the computation of moments of the survival distribution, and the full distribution p(t|x, D) can be visualized for the individual patient, as shown in Figure 5 .
From a clinical point of view, the methodology presented permits the analysis of distributions over true survival times in years and months for the individual patient, directly from gene expression data. Such an analysis may aid a clinician in evaluating treatment options, in particular since the method presented provides probabilistic statements along with the prediction made, such as the variance, and full distributions over survival times are available. Patients may benefit from such advanced predictions in the future, and receive more appropriate therapies based on a refined assessment of their individual risk.
